Jove
Visualize
Contact Us

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.7K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.7K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

547
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
547

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The colder, the better? Sustainability in frozen storage of a monoclonal antibody drug substance.

International journal of pharmaceutics: X·2026
Same author

Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development.

Bioanalysis·2026
Same author

In-depth Evaluation of the Olink Target 48 Cytokine Panel: Inter-Laboratory Evaluation of Performance and Reliability for Biomarker Studies in Oncology.

The AAPS journal·2026
Same author

Magnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Do we worry too much about polysorbate degradation? An industry-wide perspective with real-life case studies.

Journal of pharmaceutical sciences·2026
Same author

Best practices in the application of parallelism for biomarker assay validation.

The AAPS journal·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.9K

New FDA draft guidance on immunogenicity.

Ashwin Parenky1, Heather Myler, Lakshmi Amaravadi

  • 1Mercer University, 3001 Mercer University Drive, Atlanta, Georgia, 30341, USA, 10909990@live.mercer.edu.

The AAPS Journal
|April 1, 2014
PubMed
Summary

The US Food and Drug Administration (FDA) released draft guidance in 2013 on assessing immunogenicity for therapeutic protein products. Discussions focused on risk, patient safety, efficacy, and mitigation strategies for biologics.

More Related Videos

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

12.2K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

9.2K

Related Experiment Videos

Last Updated: May 1, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
06:18

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

3.9K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

12.2K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

9.2K

Area of Science:

  • Biopharmaceutical Development
  • Drug Safety and Efficacy
  • Immunology

Background:

  • A 2013 American Association of Pharmaceutical Scientists-National Biotech Conference session addressed the US Food and Drug Administration's (FDA) draft guidance on Immunogenicity Assessment for Therapeutic Protein Products.
  • The guidance focuses on evaluating immunogenicity risks associated with therapeutic proteins and their potential impact on patient safety and product efficacy.

Framework:

  • The FDA presented key aspects of the 2013 draft guidance, emphasizing immunogenicity risk assessment and mitigation strategies.
  • The draft guidance provides a framework for evaluating the immunogenic potential of therapeutic protein products.

Implementation:

  • Biopharmaceutical industry delegates engaged the FDA in open discussions regarding the draft guidance.
  • Key discussion topics included clinical impact, immune mitigation, prediction of immunogenicity, and the role of formulation, excipients, aggregates, and degradation products.

Implications:

  • The session facilitated a multidisciplinary dialogue on critical factors influencing immunogenicity in therapeutic proteins.
  • Understanding and addressing immunogenicity is crucial for ensuring the safety and efficacy of protein-based therapeutics.